Mesoblast (MESO) EBIT: 2014-2023
Historic EBIT for Mesoblast (MESO) over the last 8 years, with Jun 2023 value amounting to -$43.4 million.
- Mesoblast's EBIT rose 28.99% to -$43.4 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$10.3 million, marking a year-over-year increase of 53.45%. This contributed to the annual value of -$62.0 million for FY2025, which is 4.74% up from last year.
- Per Mesoblast's latest filing, its EBIT stood at -$43.4 million for Q2 2023, which was down 481.57% from $11.4 million recorded in Q1 2023.
- Mesoblast's 5-year EBIT high stood at $33.5 million for Q3 2019, and its period low was -$97.3 million during Q2 2021.
- Over the past 3 years, Mesoblast's median EBIT value was $11.3 million (recorded in 2022), while the average stood at -$11.6 million.
- Examining YoY changes over the last 5 years, Mesoblast's EBIT showed a top increase of 118.94% in 2021 and a maximum decrease of 3,928.91% in 2021.
- Over the past 5 years, Mesoblast's EBIT (Quarterly) stood at $18.0 million in 2019, then declined by 6.61% to $16.8 million in 2020, then fell by 16.44% to $14.0 million in 2021, then dropped by 25.32% to $10.5 million in 2022, then grew by 28.99% to -$43.4 million in 2023.
- Its EBIT was -$43.4 million in Q2 2023, compared to $11.4 million in Q1 2023 and $10.5 million in Q4 2022.